Clinical Trial Update: A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME) [Phase 1]

View source ↗

Summary

This is a Phase 1 open-label study evaluating teprotumumab for diabetic macular edema that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Teprotumumab (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Diabetic Macular Edema | Phase 1 | Status: COMPLETED